UNSPSC 51432305: Losartan

This classification denotes an angiotensin ii receptor antagonist with the molecular formula C22H23ClN6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JMS50MPO89, chemically known as 1h-imidazole-5-methanol, 2-butyl-4-chloro-1-((2-(1h-tetrazol-5-yl)(1,1- biphenyl)-4-yl)methyl)- but generally known as losartan, which bears US NIH Compound Identifier 3961. European Medicines Agency schedules Losartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08593MIG.

UNSPSC 51432305 Losartan is a Commodity code covering prescription medications supplied to state and local emergency services, health departments, and multi-jurisdictional pharmacy benefit programs. State and local governments buying under this code procure generic pharmaceuticals and branded medications for emergency medical services, public health agencies, and cooperative purchasing alliances serving multiple jurisdictions. The work encompasses supply agreements with competitive pricing, product specifications by National Drug Code, compliance with FDA and manufacturing standards, and delivery within specified timeframes. Issuing bodies include city fire rescue departments, state health and human services agencies, and cooperative purchasing organizations serving multiple states; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) coordinates procurement across participating state and local facilities in multiple jurisdictions.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications (response deadline April 8, 2026) requiring four specific medication line items for Tampa Fire Rescue with nine-month minimum expiration dates and firm pricing including freight to Tampa, with an estimated contract value of $40,000.00 and a 5 percent Small Local Business Enterprise bid discount available. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs for state pharmacy benefit initiatives, seeking vendor capabilities in negotiated net pricing and outcomes-based agreements outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 (response deadline March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers to participating state and local facilities including Oregon, requiring NDC-level product specifications, cGMP and Drug Supply Chain Security Act compliance, and pricing weighted 75 percent of evaluation criteria against administrative and technical factors.